China-based CanSino Biologics (SHA: 688185, HKG: 6185) is poised to acquire an undisclosed amount of shares in Malaysia-headquartered Solution Group Berhad, a strategic move aimed at expanding its market footprint in Southeast Asia.
Collaboration in the Vaccine Sector
Previously, CanSino Bio entered into a partnership with Solution’s subsidiary, Solution Biologics Sendirian Berhad (SOLBIO), in the vaccine sector. This collaboration includes a trilateral cooperation agreement with the National Institutes of Biotechnology Malaysia (NIBM) signed in May this year. The agreement focuses on bolstering the development of human vaccines in both countries, as well as technology transfer and manufacturing of COVID-19 vaccines.
Solution Group Berhad: A Strategic Investment
Solution Group Berhad, an investment controlling company with a focus on engineering, biopharmaceutical, and healthcare industries, established its biomedicine unit SOLBIO in 2020. This move was accompanied by the launch of the country’s first BSL2 vaccine plant, marking a significant step in the region’s biopharmaceutical capabilities.-Fineline Info & Tech
